{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-26-000027","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.764271+00:00","generated_at":"2026-05-15T08:39:02.862732+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"USPTO reaffirms Broad Institute's CRISPR/Cas9 patent priority; Editas' licensed patents upheld","bullets":["PTAB issued third favorable decision for Broad over CVC on CRISPR/Cas9 editing in eukaryotic cells.","CVC retains the right to appeal to the U.S. Court of Appeals for the Federal Circuit.","Editas' exclusive license to the CRISPR/Cas9 patents at issue remains intact; other in-licensed patents not impacted.","CEO Gilmore O'Neill cites confidence in IP, highlighting EDIT-401 with >90% mean LDL reduction in NHPs."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-26-000027","json":"https://secwatch.observer/filing/0001650664-26-000027.json","markdown":"https://secwatch.observer/filing/0001650664-26-000027.md","text":"https://secwatch.observer/filing/0001650664-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000027/0001650664-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000027/edit-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:39:02.862732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}